{"entity":{"id":"nct07767994","kind":"trial","name":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer","aka":["ICORE-GBC"],"tldr":"A phase 2 trial of ivonescimab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital Xi'an Jiaotong University, not yet recruiting.","summary":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer is a phase 2 interventional study registered as NCT07767994 by First Affiliated Hospital Xi'an Jiaotong University, with a registry enrolment figure of 22 participants, started 2026-08-28 and due to reach its primary completion in 2028-06-30. Interventions recorded: AK112, Gemcitabine, Cisplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel. Conditions listed: Gallbladder Cancer. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07767994","url":"https://clinicaltrials.gov/study/NCT07767994"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["ivonescimab","gemcitabine","cisplatin","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07767994","phase":"2","setting":"Single-Center, Single-Arm, Two-Stage, Prospective Phase II Clinical Study of AK112 Combined With GAP Regimen as Conversion Therapy for Locally Advanced Gallbladder Cancer","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","enrolled":22,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07767994/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}